3.0.0 771 2023-01-11T13:36:11Z 2023-01-11T13:36:11Z Senate S 2017-03-29 115 ssfi00 Finance Committee Senate Standing Referred to 2017-03-29T21:24:40Z 115 6340 HR 2018-07-11 Referred to the House Committee on Energy and Commerce. Related bill CRS 115 252 S 2017-02-01 Read twice and referred to the Committee on Finance. Related bill CRS 115 348 S 2017-02-09 Read twice and referred to the Committee on Finance. Related bill CRS 115 469 S 2017-02-28 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS 115 3411 S 2018-09-05 Read twice and referred to the Committee on Finance. Related bill CRS 115 2478 S 2018-03-01 Read twice and referred to the Committee on Finance. Related bill CRS 115 1776 HR 2017-04-05 Referred to the Subcommittee on Health. Identical bill CRS 115 1245 HR 2017-03-03 Referred to the Subcommittee on Health. Related bill CRS 115 2476 S 2018-02-28 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Related bill CRS 115 1688 S 2017-08-01 Read twice and referred to the Committee on Finance. Related bill CRS 2017-03-29 ssfi00 Finance Committee Senate Read twice and referred to the Committee on Finance. IntroReferral 2017-03-29 Introduced in Senate IntroReferral 10000 9 Library of Congress F000457 Sen. Franken, Al [D-MN] Al Franken D MN N S000033 Sen. Sanders, Bernard [I-VT] Bernard Sanders I VT 2017-03-29 True W000802 Sen. Whitehouse, Sheldon [D-RI] Sheldon Whitehouse D RI 2017-03-29 True B000944 Sen. Brown, Sherrod [D-OH] Sherrod Brown D OH 2017-03-29 True K000367 Sen. Klobuchar, Amy [D-MN] Amy Klobuchar D MN 2017-03-29 True W000817 Sen. Warren, Elizabeth [D-MA] Elizabeth Warren D MA A. 2017-03-29 True B001230 Sen. Baldwin, Tammy [D-WI] Tammy Baldwin D WI 2017-03-29 True R000122 Sen. Reed, Jack [D-RI] John Reed D RI F. 2017-03-29 True G000555 Sen. Gillibrand, Kirsten E. [D-NY] Kirsten Gillibrand D NY E. 2017-03-29 True H001076 Sen. Hassan, Margaret Wood [D-NH] Maggie Hassan D NH 2017-03-29 True D000563 Sen. Durbin, Richard J. [D-IL] Richard Durbin D IL J. 2017-03-29 True V000128 Sen. Van Hollen, Chris [D-MD] Chris Van Hollen D MD 2017-03-29 True M001176 Sen. Merkley, Jeff [D-OR] Jeff Merkley D OR 2017-03-29 True U000039 Sen. Udall, Tom [D-NM] TOM UDALL D NM 2017-03-29 True B001277 Sen. Blumenthal, Richard [D-CT] Richard Blumenthal D CT 2017-03-29 True B001288 Sen. Booker, Cory A. [D-NJ] Cory Booker D NJ 2017-03-29 True Health Administrative law and regulatory procedures Administrative remedies Business records Canada Cancer Civil actions and liability Competition and antitrust Congressional oversight Consumer affairs Corporate finance and management Department of Health and Human Services Drug safety, medical device, and laboratory regulation Drug therapy Executive agency funding and structure Federal Trade Commission (FTC) Government information and archives Government studies and investigations Government trust funds Health care costs and insurance Health care coverage and access Health programs administration and funding Income tax deductions Infectious and parasitic diseases Inflation and prices Judicial review and appeals Licensing and registrations Marketing and advertising Medicaid Medical research Medicare National Institutes of Health (NIH) Prescription drugs Public contracts and procurement Research and development Retail and wholesale trades Trade restrictions User charges and fees Veterans' medical care Health

00 2017-03-29 Introduced in Senate 2018-01-24T20:37:12Z This bill amends provisions of various laws relating to prescription-drug pricing and affordability. Specifically, the bill:

• expands reporting requirements for drug manufacturers and establishes corresponding civil penalties for noncompliance;
• adds reporting requirements for certain nonprofit patient-assistance programs;
• requires the Government Accountability Office (GAO) to report to Congress on the impact of patient-assistance programs on prescription-drug pricing and expenditures;
• requires the Centers for Medicare & Medicaid Services (CMS) to negotiate prices for certain prescription drugs under the Medicare program;
• requires the GAO to report to Congress on such negotiations conducted by the CMS;
• requires the Centers for Medicare and Medicaid Innovation within the CMS to test specified models for negotiating drug prices;
• establishes reporting requirements, and corresponding civil penalties for noncompliance, for pharmaceutical companies with respect to spikes in prescription-drug prices;
• establishes an excise tax on prescription drugs subject to price spikes;
• lessens prescription-drug cost-sharing requirements under qualified health plans, group health plans, and the Medicare program;
• modifies provisions related to the importation of prescription drugs;
• requires drug manufacturers to provide drug rebates for drugs dispensed to certain low-income individuals under the Medicare program;
• establishes a prize fund for new and more effective treatments of bacterial infections;
• establishes a Center for Clinical Research within the National Institutes of Health;
• modifies provisions related to drug exclusivity;
• allows the Federal Trade Commission to initiate enforcement proceedings against parties to an agreement resolving or settling a patent-infringement claim in connection with the sale of a drug product;
• requires the Food and Drug Administration to establish a database of generic drugs; and
• modifies other provisions related to generic drugs, prescription-drug advertising, and product hopping.

]]>

Display Title Official Title as Introduced Introduced in Senate IS Short Titles as Introduced Introduced in Senate 2017-03-29T04:00:00Z https://www.govinfo.gov/content/pkg/BILLS-115s771is/xml/BILLS-115s771is.xml 2017-03-29 Read twice and referred to the Committee on Finance. text/xml EN Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain. Congressional Research Service, Library of Congress This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.